Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Clinical Pharmacokinetics

Volumn 31, Issue 5, 1996, Pages 372-385

  Özdemir, Vural ^a,b   Fourie, Jeanne ^a,b   Busto, Usoa ^a   Naranjo, Claudio A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CODEINE; CYTOCHROME P450; ISOENZYME; MIDAZOLAM; OPIATE; PSYCHOTROPIC AGENT; TRIAZOLAM;

AGED; ALCOHOL ABUSE; ALCOHOL BLOOD LEVEL; ALCOHOL WITHDRAWAL; DISEASE COURSE; DISEASE SEVERITY; DRUG ABUSE; DRUG DEPENDENCE; ETHNOLOGY; GERIATRICS; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

EID: 0029970731     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631050-00004     Document Type: Review

References (144)

1. Naranjo CA, Herrmann N, Özdemir V, et al. Abuse of prescription and licit psychoactive substances by the elderly: issues and recommendations. CNS Drugs 1995; 4 (3): 207-21
2. The use of alcohol and other drugs by older Canadians and its consequences. Catalogue No. H39-259/11992E. Ottawa: Health and Welfare Canada, 1992
3. Simons LA, Tett S, Simons J, et al. Multiple medication use in the elderly: use of prescription and non-prescription drugs in an Australian community setting. Med J Aust 1992; 157: 242-6
4. Short RI, Bauwens SF, Landefeld CS. Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. Am J Med 1990; 89: 725-32
5. Mant A, Duncan-Jones P, Saltman D, et al. Development of long term use of psychotropic drugs by general practice patients. BMJ 1988; 296: 251-4
6. Morgan K, Dallosso H, Ebrahim S, et al. Prevalence, frequency and duration of hypnotic use among the elderly living at home. BMJ 1988; 296: 601-2
7. Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines: issues relevant to prescribing. JAMA 1988; 260: 3476-80
8. Koenig W, Ruther E, Filipiak B. Psychotropic drug utilization patterns in a metropolitan population. Eur J Clin Pharmacol 1987; 32: 43-51
9. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987; 39: 251-413
10. Glynn RJ, Bouchard GR, LoCastro JS, et al. Aging and generational effects on drinking behaviors in men: results from the normative aging study. Am J Public Health 1985; 75: 1413-9
11. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985; 42: 225-32
12. Morgan K. Sedative-hypnotic drug use and ageing. Arch Gerontol Geriatr 1983; 2: 181-99
13. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 7: 89-93
14. Kruse WHH. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Saf 1990; 5: 328-44
15. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med 1988; 148: 2441-4
16. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among the elderly persons living in the community. N Engl J Med 1988; 319: 1701-7
17. Larson EB, Kukull WA, Buchner DA, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169-73
18. Ray W, Griffin M, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-9
19. Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 1978; 5: 407-13
20. Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther 1977; 21: 355-61
21. Busto UE, Lanctot KL, Bremner KE, et al. Benzodiazepine kinetics contribute to their differential abuse. Can J Clin Pharmacol 1995; 2 (1): 23-28
22. Naranjo CA, Busto UE. Dose response relationships in drug dependence in humans. In: Lasagna L, Erill S, Naranjo CA, editors. Dose-response relationships in clinical pharmacology. Amsterdam: Elsevier Science Publishers Biomedical Division, 1989: 79-92
23. Sellers EM, Busto U, Kaplan HL. Pharmacokinetic and pharmacodynamic drug interactions: implications for abuse liability testing. In: Fishman MW, Mello NK, editors. Testing for abuse liability of drugs. NIDA Res Monogr 1989; 92: 287-306
24. Busto U, Sellers EM. Pharmacokinetic determinants of drug abuse and dependence: a conceptual perspective. Clin Pharmacokinet 1986; 11: 144-53
25. Higuchi S, Matsushita S, Murayaina M, et al. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry 1995; 152: 1219-21
26. Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995; 25 (3): 277-90
27. Von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33-44
28. Robin DW, Lee M, Hasan SS, et al. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 630-7
29. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13: 434-9
30. Murray M. P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132-46
31. Durnas C, Loi C, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359-89
32. Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology 1989; 9: 331-4
33. Farrell GC. Drug metabolism in extrahepatic diseases. Pharmacol Ther 1987; 35: 375-404
34. Teng YS. Human liver aldehyde dehydrogenase in Chinese and Asiatic Indians: gene detection and the possible implication in alcohol metabolism. Biochem Genet 1981; 19: 107-13
35. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association. 1944
36. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328: 1398-405
37. Woolverton WL, Wessinger WD, Balster RL. Reinforcing properties of clonidine in rhesus monkeys. Psychopharmacology 1982; 77: 17-23
38. Meyer DR, El-Azhary R, Bierer DWS, et al. Tolerance and dependence after chronic administration of clonidine to the rat. Pharmacol Biochem Behav 1977; 7: 227-31
39. Winger GD, Stitzer M, Woods JH. Barbiturate-reinforced responding in rhesus monkeys: comparison of drugs with different durations of actions. J Pharmacol Exp Ther 1975; 195: 505-14
40. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (Pt I). Clin Pharmacokinet 1991; 21: 165-77
41. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (Pt II). Clin Pharmacokinet 1991; 21: 262-273
42. Davies KN, Castleden CM, McBurney A, et al. The effect of ageing on the pharmacokinetics of dihydrocodeine. Eur J Clin Pharmacol 1989; 37: 375-9
43. Owen JA, Sitar DS, Berger L, et al. Age-related morphine kinetics. Clin Pharmacol Ther 1983; 34: 364-8
44. Pozzato G, Moretti M, Franzin F, et al. Ethanol metabolism and aging: the role of 'first pass metabolism' and gastric alcohol dehydrogenase activity. J Gerontol 1995; 50A (3): B135-41
45. Vestal RE, McGuire EA, Tobin JD, et al. Aging and ethanol metabolism. Clin Pharmacol Ther 1976; 21: 343-54
46. Busto U, Lanctot KL, Isaac P, et al. Benzodiazepine use and abuse in Canada. Can Med Assoc J 1989; 141: 917-21
47. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956-966
48. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989; 29: 866-72
49. Rodrigo EK, King MB, Williams P. Health of long term benzodiazepine users. BMJ 1988; 296: 603-6
50. Shader RI, Greenblatt DJ. Benzodiazepine overuse-misuse. J Clin Psychopharmacol 1984; 4: 123-4
51. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-8
52. Ammon E, Schafer C, Hofmann U, et al. Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther 1996; 59: 503-13
53. Wagner JG. Intrasubject variation in elimination half-lives of drugs which are appreciably metabolized. J Pharmacokinet Biopharm 1973; 1: 165-73
54. Liskow BI, Rinck C, Campbell J. Alcohol withdrawal in the elderly. J Stud Alcohol 1989; 50: 414-21
55. Shibuya A, Yoshida A. Frequency of the atypical aldehyde dehydrogenase-2 gene (ALDH2) in Japanese and Caucasians. Am J Hum Genet 1988; 43: 741-3
56. Brien JF, Loomis CW. Aldehyde dehydrogenase inhibitors as alcohol-sensitizing drugs: a pharmacological perspective. Trends Pharmacol Sci 1985; 6: 478-80
57. Thomasson HR, Edenberg HJ, Crabb DW, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet 1991; 48: 677-81
58. Hawley CJ, Tattersall M, Dellaportas C, et al. Comparison of long-term benzodiazepine users in three settings. Br J Psychiatry 1994; 165: 792-6
59. Balter MB, Manheimer DI, Mellinger GD, et al. A cross-national comparison of anti-anxiety/sedative drug use. Curr Med Res Opin 1984; 8 Suppl. 4: 5-20
60. Barnhill JG, Greenblatt DJ, Miller LG, et al. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther 1990; 253: 1153-61
61. Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age. regular sedation, and alcohol. BMJ 1984; 289: 351-3
62. Swift CG, Ewen JM, Clarke P, et al. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 1985; 20: 111-8
63. 11C]Ro 15-4513. Neurosci Lett 1993; 159: 207-10
64. Evans SM, Critchfield TS, Griffiths RR. Abuse liability assessment of anxiolytics/hypnotics: rationale and laboratory core. Br J Addict 1991; 86: 1625-32
65. Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991; 86: 1563-70
66. Jasinski DR, Johnson RE, Henningfield JE. Abuse liability assessment in human subjects. Trends Pharmacol Sci 1984; 5: 196-200
67. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: diazepam. Psychopharmacology 1980; 71: 269-73
68. De Wit H, Johanson CE, Uhlenhuth EH. The dependence potential of benzodiazepines. Curr Med Res Opin 1984; 8: 48-59
69. De Wit H, Uhlenhuth EH, Johanson CE. Lack of preference for flurazepam in normal volunteers. Pharmacol Biochem Behav 1984; 21: 865-9
70. De Wit H, Uhlenhuth EH, Hedeker D. Lack of preference for diazepam in anxious volunteers. Arch Gen Psychiatry 1986; 43: 533-41
71. Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 1979; 210: 301-10
72. Griffiths RR, Bigelow GE, Liebson I, et al. Drug preference in humans: double-blind comparison of pentobarbital. diazepam, and placebo. J Pharmacol Exp Ther 1980; 215: 649-61
73. Griffiths RR, McLeod DR, Bigelow GE, et al. Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J Pharmacol Exp Ther 1984; 229: 501-8
74. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 163-8
75. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-74
76. Wynne HA, Mutch E, James OFW, et al. The effect of age upon the affinity of microsomal monooxygenase enzymes for substrate in human liver. Age Ageing 1988; 17: 401-5
77. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985; 37: 133-48
78. Woodhouse KW, Mutch E, Williams FM, et al. The effect of age on pathways of drug metabolism in human liver. Age Ageing 1984; 13: 328-34
79. Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153 (3): 311-20
80. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39 (2): 151-9
81. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-31
82. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35-9
83. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should he avoided in patients receiving the systemic antimyeotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-7
84. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-7
85. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31
86. Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-55
87. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82
88. Otton VS, Dafang W, Russell TJ, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401-9
89. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
90. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 470-86
91. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323-7
92. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazalom by human liver cytochrome P450III A4. Mol Pharmacol 1989; 36: 89-96
93. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-55
94. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
95. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1942; 51: 388-47
96. Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p (4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483-7
97. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol 1985; 38: 402-8
98. Crowley JJ, Cusack BJ, Jue SG, et al. Induction of theophylline metabolism by phenytoin is unaltered by aging. Clin Res 1986; 34: 396A
99. Twum-Barima Y, Finnigan T, Habush Al, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984; 17: 595-6
100. Cusack BJ, Kelly JG, Lavan J, et al. Theophylline kinetics in relation to age: The importance of smoking. Br J Clin Pharmacol 1980; 10: 109-14
101. Mucklow JC, Fraser HS. The effects of age and smoking upon antipyrine metabolism. Br J Clin Pharmacol 1980; 9: 63-4
102. Salem SAM, Rajjayabun P, Shepherd AMM, et al. Reduced induction of drug metabolism in the elderly. Age Ageing 1978; 7: 68-73
103. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking, Clin Pharmacol Ther 1975; 18: 425-32
104. Bigelow GE. Human drug abuse liability assessment: opioids and analgesics. Br J Addict 1991; 86: 1615-28
105. Adler TK, Fujimoto JM, Way EL, et al. The metabolic fate of codeine in man. J Pharmacol Exp Ther 1955; 114: 251-62
106. Yue QY, Svensson JO, Alm C, et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989; 28: 639-45
107. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988; 2: 914-5
108. Guay DRP, Awni WM, Findlay JWA, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43: 63-71
109. Yue QY, Hassclström J, Svensson JO, et al. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991; 31: 635-42
110. Paul D, Standifer KM, Inturrisi CE, et al. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251: 477-83
111. Quiding H, Anderson P, Bondesson U, et al. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 1986; 30: 673-7
112. Sanfilippo G. Contributo sperimentale all'ipotesi della smetilazione della codeina nell'organismo: I. Influenze della dose sull'assuefazione alla codeina. II. Assuefazione alla codeina attenuta con somministrazione prolungata di morfina. Boll Soc Ital Biol Sper 1948; 24: 723-6
113. Persson K, Sjöstrom S, Sigurdardottir I, et al. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995; 39: 182-6
114. Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41: 23-6
115. Irvine RJ, Chen ZR, Somogyi AA, et al. μ-opioid receptor binding affinity of some opiates and their metabolites. Life Sci 1991; 48: 2165-71
116. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1991; 49: 686-93
117. Shah JC, Mason WD. Plasma codeine and morphine concentrations alter a single oral dose of codeine phosphate. J Clin Pharmacol 1990; 30: 764-6
118. Guay DRP, Awni WM, Halstenson CE, et al. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol 1987; 27: 983-7
119. Dahlstrom B, Tamsen A, Paalzow L, et al. Patient-controlled analgesic therapy (Pt IV): pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982; 7: 266-79
120. Quiding H, Oikarinen V, Sane J, et al. Analgesic efficacy after single and repeated doses of codeine and acetaminophen. J Clin Pharmacol 1984; 24: 27-34
121. Young RES. A two dose evaluation of propoxyphene napsylate and codeine in postoperative pain. Curr Ther Res 1978; 24: 495-502
122. Gruber CM. Codeine and propoxyphene in postepisiotomy pain: a two dose evaluation. JAMA 1977; 237: 2734-2735
123. Osborne R, Thompson P, Joel S, et al. the analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-8
124. Hand CW, Blunnie WP, Claffey LP, et al. Potential analgesic contribution from morphine-6-glucuronide in CSF. Lancet 1987; II: 1207-8
125. Shimomura K, Kamata O, Ueki S, et al. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45-52
126. Davies KN, Castleden CM, McBurney A, et al. The effect of ageing on the pharmacokinetics of dihydrocodeine. Eur J Clin Pharmacol 1989; 37: 375-9
127. Baillie SP, Bateman DN, Coates PE, et al. Age and the pharmacokinetics of morphine. Age Ageing 1989; 18: 258-62
128. Bodd E, Beylich KM, Christophersen AS, et al. Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. Pharmacol Toxicol 1987; 61: 297-300
129. Rogers JF, Findlay JW, Hull JH, et al. Codeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 218-27
130. Steiner E, Iselius L, Alvan G, et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1985; 38: 394-401
131. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet 1992; 17: 115-20
132. Romach MK, Sproule B, Kathiramalainathan K, et al. Developing medication strategies as adjuncts to treating prescription opiate dependence and comorbidity. In: Harris LS, editor. Problems of drug dependence. Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville: US Department of Health and Human Services, 1996: 120
133. Teri L, Rabins P, Whitehouse P, et al. Management of behavior disturbance in Alzheimer disease: current knowledge and future direction. Alzheimer Dis Assoc Disord 1992; 6: 77-88
134. Ancill RJ, Holliday SG. Treatment of depression in the elderly: a Canadian view. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 655-61
135. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl. 5: 9-15
136. Blazer DG, Bachar JR, Manton KG. Suicide in late life: review and commentary. J Am Geriatr Soc 1986; 34: 519-25
137. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46: 377-94
138. Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12-7
139. Agundez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-9
140. Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-20
141. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63
142. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9
143. Yue QY, Svensson JO, Sjöqvist F, et al. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol 1991; 31: 643-7
144. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102-7